Cerebrospinal fluid (CSF) specimens from 22 allogeneic bone marrow transplant patients with central nervous system (CNS) symptoms (cases) and 107 patients who were immunocompromised but did not have CNS symptoms (controls) were assayed for human herpesvirus 6 (HHV-6) DNA. HHV-6 DNA was detected in CSF specimens from five (23%) of 22 cases and in CSF specimens from one (0.9%) of 107 controls (P õ .001, Fisher's exact test). In addition, none of the five cases with HHV-6 DNA detected in CSF samples had any other identified cause of their CNS symptoms, and none of the other 11 cases with known causes for their CNS diseases had HHV-6 DNA detected in CSF samples (P Å .03, Fisher's exact test). In three cases, HHV-6 variant B was identified, and the HHV-6 variant could not be defined in the other two cases. Prophylaxis with acyclovir did not prevent the occurrence of HHV-6-associated CNS disease after allogeneic bone marrow transplantation. Four cases' conditions were improved or they were cured after treatment with either ganciclovir or foscarnet, and one case died of CNS disease despite foscarnet treatment.
The incidence of CNS complications after allogeneic bone in vitro [17 -20] . HHV-6 variant B strains are also susceptible to ganciclovir, while variant A may be less susceptible [17 -marrow transplantation (BMT) varies between 11% and 37% at different BMT centers, and CNS disease is frequently associ -21] . There are no data available regarding the need for and efficacy of antiviral therapy for HHV-6 infections in patients ated with a fatal outcome [1 -4] . Several different etiologies of CNS symptoms in patients who have undergone BMT have who have undergone allogeneic BMT; thus, further studies on the role of HHV-6 in CNS disease after allogeneic BMT are been described, such as pulmonary compromise, renal failure, hepatic dysfunction, hemorrhage in the CNS, drug toxicity, and warranted since HHV-6 is susceptible to the antiviral drugs mentioned above. various kinds of infections. However, a large proportion of CNS symptoms after BMT remain unexplained.
The aims of this study were to analyze the frequency of HHV-6 DNA detection in CSF specimens from immunocomHuman herpesvirus 6 (HHV-6) is a recently discovered herpesvirus, and HHV-6 isolates can be classified into variants A promised patients with or without CNS symptoms and to elucidate the clinical significance of detectable HHV-6 DNA in CSF and B according to DNA sequences, cell tropism in vitro, and antigenicity [5] . HHV-6 can infect glial cell lines, and both of after allogeneic BMT. the HHV-6 variants can productively infect primary astrocytes [6 -8] . Previous studies have suggested that HHV-6 can invade
Patients and Methods the CNS during primary infection and that the CNS may be one site of latency for HHV-6 [9 -11] . Cases of fatal CNS Controls. Ninety-four CSF samples were collected from 74 infections caused by HHV-6 have been described in immunopediatric patients (mean age, 6.5 years; range, 1-18 years) before competent individuals as well as in patients infected by HIV they received intrathecal prophylaxis for CNS leukemia with or liver transplant recipients [12 -15] . One case of fatal encephmethotrexate as part of chemotherapy for hematologic malignanalitis due to HHV-6 variant B has been reported after allogeneic cies at Hospital S. Gerardo, Monza, Italy. In addition, 41 CSF BMT [16] . Both HHV-6 variants are susceptible to foscarnet samples were collected from 29 patients with hematologic malignancies 1 week before BMT and from 6 patients after allogeneic or autologous BMT at routine CSF examinations or before intrathecal prophylaxis for CNS leukemia at Huddinge University
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Hospital, Huddinge, Sweden, or at Hospital S. Gerardo. Two
Informed consent was obtained from all subjects donating specimens in the course of this research.
patients donated CSF specimens both before and after BMT;
Financial support: This study was supported by the Swedish Children's therefore, the total number of controls was 107. The characterisCancer Foundation.
tics of the controls are given in table 1. emptive therapy based on the results of PCR analysis, but some patients also received high doses of acyclovir (500 mg/m 2 intraveNo CSF samples from two of the 24 patients with CNS symptoms were available for analysis of HHV-6 DNA, and nously three times daily) or valacyclovir (2,000 mg orally four times daily) as prophylaxis for CMV infection. these two patients were excluded from the study. Of these two patients, one had verified CNS leukemia, and the other had Four of the 22 cases were receiving antiviral prophylaxis at the time when CNS symptoms developed: one with high doses bacterial meningitis. Two CSF samples were collected from two patients before BMT at routine CSF examination, and one of acyclovir, one with low doses of acyclovir, and two with valacyclovir. Prophylaxis for three patients was discontinued CSF sample was collected from one patient 2 weeks before CNS symptoms were noticed. Twenty-four CSF samples were at the time of CNS symptoms. Valacyclovir therapy was continued for the fourth patient because of an unclear etiology of the collected from 22 patients at the time of CNS symptoms, and four CSF samples were collected from four patients after recov-CNS symptoms. No patient in this study had received prophylactic ganciclovir or foscarnet. ery following antiviral therapy. Therefore, 31 CSF samples from 22 patients with CNS symptoms (cases) were available Identification of pathogens causing CNS symptoms. All 22 cases were routinely screened for infection with bacterial, funfor analysis in this study. The characteristics of the 22 cases are shown in table 1. Fourteen of the 22 cases had unrelated gal, and virological agents by isolation, serology, or PCR analysis at Huddinge University Hospital. All the CSF samples were donors, while eight had HLA identical sibling donors.
In addition to the CSF samples, 30 peripheral blood leukocyte analyzed for DNA from HSV types 1 and 2 and CMV by PCR methods. PCR analyses for varicella-zoster virus (VZV), (PBL) samples were collected from six of the 22 cases before and during the period when CNS symptoms were noticed.
Epstein-Barr virus (EBV), enterovirus, and JC and BK viruses were also performed if clinically suggested. Routine PCR methThe study was approved by the Ethical Committees at Huddinge University Hospital and Hospital S. Gerardo.
ods at the Department of Virology, Huddinge University Hospital, were used. Finally, CSF samples also underwent histopathConditioning regimens. Patients with malignancies were treated either with cyclophosphamide (60 mg/kg) for two conologic examination and fluorescence-activated cell sorting analysis for malignant cells. secutive days followed by total body irradiation (TBI; 10 Gy with the lungs shielded for a dose of 9 Gy) or with busulfan Of the 22 cases, 11 had the etiology of the CNS symptoms identified by the methods described above. The infectious etio-(4 mg/kg) for four consecutive days followed by cyclophosphamide (60 mg/kg) for two consecutive days. Patients with aplaslogies were as follows: HSV type 1, 1 patient; VZV, 2; CMV, 1; EBV, 1; parainfluenza virus, 1; and enterovirus, 1. The other tic anemia were treated with cyclophosphamide (50 mg/kg) together with antithymocyte globulin for four consecutive days.
causes were drug toxicity (2 patients), bleeding in the CNS (1), and leukemia relapse in the CNS (1). It is interesting that Children with metabolic disorders were given therapy with busulfan and cyclophosphamide. Patients with nonmalignant one (0.5%) of 182 patients with matched sibling donors vs. six (4.3%) of 140 patients with unrelated donors had a viral etioldiseases and unrelated donors were usually treated with cyclophosphamide in combination with TBI, although other regiogy of the CNS symptoms (P Å .046, Fisher's exact test).
Definitions. Engraftment of neutrophils was defined as an abmens were also used in individual cases. Of the 22 cases included in this study, 15 received TBI, while seven did not.
solute neutrophil count of ú0.5 1 10 9 /L for two consecutive days;
/ 9c63$$mr01 02-24-99 07:46:13 cida UC: CID engraftment day of platelets or RBCs was defined as the first day HHV-6 DNA was detected in the CSF sample from one patient 2 weeks before the CNS symptoms appeared and in after transfusion for platelets or RBCs, respectively, was stopped. Acute GVHD was defined according to Thomas et al. [22] .
CSF samples from four patients at the time when CNS symptoms were noticed. Three of the HHV-6 DNA -positive CSF Preparation of CSF samples for PCR analysis for HHV-6 and human herpesvirus 7 (HHV-7). CSF samples were stored samples contained HHV-6 variant B, and the HHV-6 variants in the other two samples could not be defined. Of the five at 020ЊC before analysis. CSF samples were heated for 15 minutes at 94ЊC, and 10 mL was used for each PCR analysis.
patients with detectable HHV-6 DNA in CSF samples, two patients had CSF samples available before allogeneic BMT, and three Detection of HHV-6 and HHV-7. Two previously reported nested PCR methods were used for detection of HHV-6 DNA patients had CSF samples collected after antiviral therapy when the CNS symptoms abated; HHV-6 DNA was not detected in any and HHV-7 DNA, respectively [23, 24] . The PCR method for HHV-6, which yields a final product of 130 bp, has a sensitivity of these CSF samples. In addition, no other microbiological causes were detected in any of the CSF samples, and none of the CSF of 20 -30 genomes for HHV-6 variants A and B. HHV-6 variants A and B were also differentiated by a previously described samples contained malignant cells.
Detection of HHV-6 DNA in PBL samples from the five cases nested PCR method, which yields products of different sizes for each variant [24] . The sensitivity of the PCR method for with detectable HHV-6 DNA in CSF samples. Nineteen PBL samples were collected weekly from four of the five cases with HHV-6 is around 50 genomes for both HHV-6 variants. The sensitivity of the PCR method for HHV-7 has not been defined.
detectable HHV-6 DNA in CSF samples before and during the time when CNS symptoms were noticed. HHV-6 DNA was Sterilized water was used as a negative control for every three to five CSF samples in the PCR methods for both HHV-6 and detected in 15 of 18 PBL samples from three cases (nos. 2, 4, and 5 in table 2). In all three cases, HHV-6 variant B was HHV-7. Culture supernatant from the GS strain and/or Z 29 strain was used as a positive control for the PCR assays for HHV-6. detected in PBL samples. There was only one PBL sample available from case 3. This sample was collected at the time An HHV-7 DNA-positive saliva sample from a patient with AIDS was used as a positive control for the PCR assays for HHVwhen CNS symptoms were noticed. HHV-6 DNA was not detected in this PBL sample. 7. All the CSF samples from the cases were analyzed at least twice in the PCR assays for both HHV-6 and HHV-7.
CNS symptoms of the five cases with detectable HHV-6 DNA in CSF specimens. The types of CNS symptoms of the five Detection of HHV-6 DNA in peripheral blood leukocyte (PBL) samples. PBL samples were analyzed for HHV-6 DNA cases with detectable HHV-6 DNA in CSF samples are shown in table 2. All five cases had symptoms characterized as encephand HHV-6 variants according to a previously reported method with the same PCR methods as described above [23] . DNA alitis including confusion (four of five) and somnolence (three of five). Three cases developed CNS symptoms before enrepresenting 5 1 10 4 PBLs was used for each PCR assay. PCR assay of PBL samples for HHV-6 was performed in the same graftment, while two developed CNS symptoms after engraftment. The three cases with early CNS symptoms were way as that for the CSF samples, and the HHV-6 variants in the PBL samples were differentiated by the same method as more severely affected. Biochemistry analysis of CSF samples showed elevated aldescribed above.
bumin levels in all four cases analyzed. One patient had an elevated WBC count with a predominance of mononuclear Results cells. The electroencephalogram showed mild or severe diffuse abnormalities in all four cases analyzed. CT indicated pathologDetection of HHV-6 DNA in CSF samples from controls. HHV-6 DNA was detected in two (1.5%) of 135 CSF samples ical changes in only two cases, and in case 3, a subarachnoid hemorrhage that was indicated by CT could not be confirmed from the controls. The two CSF samples with detectable HHV-6 DNA were collected from the same patient 4 months apart, at autopsy performed 2 days later. MRI showed signs of an old hemorrhage in one of three cases analyzed, while the other but no CNS symptoms were noticed during this period or later during 2 years of follow-up. Thus, HHV-6 DNA was detected two scans were normal. The clinical characteristics, treatment regimens, and outin CSF samples from one (0.9%) of 107 controls.
Detection of HHV-6 DNA in CSF samples from cases. comes of the five cases with detectable HHV-6 DNA in CSF specimens are shown in table 3. Four patients were receiving HHV-6 DNA was detected in five (16%) of 31 CSF samples from five (23%) of 22 cases. Furthermore, none of the five antiviral prophylaxis or antiviral treatment when the CNS symptoms appeared. One case was receiving high doses of cases with detectable HHV-6 DNA in CSF samples had any previously defined cause of their CNS symptoms. Thus, five acyclovir, one was receiving valacyclovir, and two were receiving ganciclovir (5 mg/kg intravenously twice daily) as preemp-(45%) of 11 cases without previously defined causes of their CNS symptoms compared with zero of 11 cases with previously tive therapy for CMV infection. All the five cases received antiviral therapy after the appearance of CNS symptoms. Four defined causes of their CNS symptoms had detectable HHV-6 DNA in CSF samples (P Å .03, Fisher's exact test). HHV-7 cases were treated with foscarnet (60 mg/kg intravenously three times daily), and one was treated with ganciclovir (5 mg/kg DNA was not detected in any of the 31 CSF samples.
/ 9c63$$mr01
02-24-99 07:46:13 cida UC: CID intravenously twice daily). HHV-6 DNA was not detected in of treatment, and the treatment was continued for another 2 weeks at full doses after the symptoms disappeared. No patient any of the three CSF samples from cases 2, 4, and 5, respectively, after foscarnet treatment and recovery.
received chronic suppressive antiviral therapy. The CNS disease in case 3 progressed rapidly, and the patient Three cases were considered cured: case 1 survived for 3 weeks without CNS symptoms and died of bleeding, and cases died despite treatment with foscarnet. An autopsy was performed. Tissue specimens from the white matter of the frontal 4 and 5 were still alive ú2 years after BMT and were well without CNS symptoms. Case 2 responded to foscarnet therapy lobe of the cerebral cortex, basal ganglia, medulla oblongata, and pons were abnormal, and the pathology consisted of diffuse with improved mental status but died later of multiple organ failure. The patients recovered within 1 -2 weeks after the start edema, perivascular aggregates of monocytes and macro- / 9c63$$mr01 02-24-99 07:46:13 cida UC: CID phages, microglial proliferation, and accumulation of granulounlikely explanation since the numbers of WBCs in the HHV-6 DNA-positive CSF samples were very low and either HHVcytes and monocyte-like inflammatory cells in the tissues. The leptomeninges were fibrotic. No abnormality was observed in 6 DNA was undetectable or the levels of HHV-6 DNA were too low in the PBL samples from these patients to cause significant the cerebral cortex, hippocampal gyrus, mesencephalon, or cerebellum. The involved brain tissues were screened for DNA contamination of CSF considering the WBC content of these CSF samples (data not shown). from HSV types 1 and 2, VZV, CMV, EBV, JC virus, adenovirus, and HHV-6 by the same PCR methods that were mentioned
We have previously shown that patients who undergo allogeneic BMT frequently have several of the lymphotropic herpesunder Patients and Methods, and only HHV-6 DNA was detected in the involved brain tissues.
viruses detectable in PBL samples during the first months after BMT [23] . HHV-7 is closely related to HHV-6 and has also Four of 14 cases with unrelated donors had HHV-6-associated CNS disease vs. one of eight cases with HLA identical been reported as a cause of exanthem subitum and CNS symptoms [30, 31] . HHV-7 DNA, however, was not detected in any sibling donors. In addition, four of 15 cases who underwent TBI had HHV-6 DNA detected in CSF samples vs. one of of the CSF samples from the 22 cases. The results of a retrospective comparison can be influenced seven cases who did not undergo TBI.
by the choice of the control population. We chose a population of immunosuppressed patients to mimic the population for Discussion whom HHV-6 might be a clinical problem. It could be argued that the relevant controls might be either healthy individuals CNS symptoms are common in patients who have undergone allogeneic BMT, and the cause of the symptoms frequently or a group including only patients who have undergone BMT. We believe that there would be no advantage to using healthy remains undetermined. In our study, the incidence of CNS disease among patients who underwent allogeneic BMT was controls since we found only one control with HHV-6 DNA in the CSF sample, and it is unlikely that HHV-6 would have 7%, which is similar to rates in previous reports [1 -4] .
HHV-6 can actively infect glial cell lines and primary astrobeen more common in CSF specimens from immunocompetent individuals. Regarding the use of only patients who have undercytes, and cases of CNS infection with HHV-6 have been described in both immunocompromised patients and immunogone BMT, two control populations of patients who underwent BMT were in fact used in this study: asymptomatic patients competent individuals [9 -16] . There is no established clinical or radiological method to differentiate HHV-6 infections from and patients with other clearly defined causes of the CNS symptoms. HHV-6 DNA was not found in the CSF specimens from other CNS complications after allogeneic BMT. A significant correlation between detection of CMV and other viral DNA in any of these patients who had undergone BMT. Thus, our data suggest that the role of HHV-6 as a pathogen CSF and viral meningitis or encephalitis has been indicated in recent reports [25 -27] . However, HHV-6 DNA can be detected of CNS disease after allogeneic BMT might be underestimated.
The results of a recent study involving patients with AIDS in normal brain tissues as well as in cellular components of CSF collected from patients with noninflammatory neurologishowed that only 2% of 500 AIDS patients with CNS symptoms due to other causes had HHV-6 DNA detected in CSF cal symptoms [10, 28, 29] . Data regarding detection of HHV-6 in CSF samples from immunocompromised patients without samples [32] . This finding suggests that the detection of HHV-6 DNA in CSF together with clinical symptoms of a CNS CNS symptoms are lacking; therefore, it has been difficult to assess the importance of detection of HHV-6 DNA in CSF infection should be assumed to be a finding of clinical relevance. specimens from immunocompromised patients presenting with CNS symptoms.
An increasing number of patients undergoing allogeneic BMT receive transplants from unrelated donors. The intensified We detected HHV-6 DNA in CSF samples from five (45%) of 11 patients with CNS symptoms of undefined origin after immunosuppression needed as prophylaxis for acute GVHD and acute GVHD itself probably predispose patients to viral allogeneic BMT (cases). In contrast, HHV-6 DNA was detected in the CSF sample from only one (0.9%) of 107 immunocomreactivations. In our study, viral infections of the CNS were more frequent in patients whose transplants were from unrepromised patients without CNS symptoms (controls) and in none of the 11 patients who underwent BMT for whom other lated stem cell donors, including four of the five cases with CNS disease possibly due to HHV-6. Patients with unrelated causes for the CNS diseases were documented (cases). Furthermore, HHV-6 DNA was not detected either in the CSF samples donors are usually more immunosuppressed than those with HLA identical sibling donors, which may increase the risk for collected before BMT or in the CSF samples collected after the CNS symptoms had abated following antiviral therapy. viral infection of the CNS. It might be possible that TBI may lead to HHV-6 reactivation in the CNS. However, this possibilThese data support a causative role for HHV-6 in these cases of encephalitis. ity was not supported by our data since our series included only five cases. Another possible explanation for the detection of HHV-6 DNA in CSF could be that PBLs containing HHV-6 DNA had HHV-6 may affect both gray and white matter as well as the hippocampus and lead to progressive mental deterioration ''contaminated'' the CSF. However, we believe that this is an / 9c63$$mr01 02-24-99 07:46:13 cida UC: CID after allogeneic BMT [16] . Although all five cases in our study BMT. The detection of HHV-6 DNA in CSF was related to CNS symptoms, thereby indicating that HHV-6 may be a major who had HHV-6 DNA detected in CSF samples had symptoms consistent with encephalitis and meningoencephalitis, the clinipathogen of CNS disease after allogeneic BMT. Since clinical presentations, biochemistry analysis of CSF, CT, and MRI were cal presentation was in accordance with previous reports of HHV-6 infections of the CNS [13 -16] . Like other patients not sufficient in establishing the diagnosis, the detection of HHV-6 DNA in CSF by means of PCR analysis provides an with infectious CNS complications after allogeneic BMT, the differential diagnostic value of electroencephalography, CT, important tool for both diagnosis and monitoring of therapy. MRI, and biochemistry analysis of CSF was limited.
So far, three cases of encephalitis with HHV-6 as the identi-
